肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Leap Therapeutics将DKK1单抗DKN-01亚洲开发权利许可给百济神州，用于与PD-1单抗联用

2020-01-05 不详 MedSci原创

LEAPtherapeuticsDKK1单抗DKN-01百济神州PD-1
关注

美国肿瘤免疫疗法的生物技术公司Leap Therapeutics，宣布将其靶向Dickkopf-1（DKK1）蛋白单抗DKN-01的在日本以外的亚洲、澳大利亚和新西兰开发和商业化的权利许可给百济神州。Leap将保留DKN-01在世界其他地区的开发、制造和商业化的专有权。此外，Leap宣布与百济神州和两名机构投资者达成2700万美元股权融资的协议。

美国肿瘤免疫疗法的生物技术公司Leap Therapeutics，宣布将其靶向Dickkopf-1（DKK1）蛋白单抗DKN-01的在日本以外的亚洲、澳大利亚和新西兰开发和商业化的权利许可给百济神州。Leap将保留DKN-01在世界其他地区的开发、制造和商业化的专有权。此外，Leap宣布与百济神州和两名机构投资者达成2700万美元股权融资的协议。

百济神州免疫肿瘤学首席医学官表示："很期待可以将我们的抗PD-1抑制剂tislelizumab单抗与DKN-01结合使用。与Leap的合作是我们致力于开发新颖疗法以解决亚洲和世界各地未满足的医疗需求的又一例证。"

DKN-01是一种人源化单克隆抗体，可与Dickkopf-1（DKK1）蛋白结合并阻断其活性，Dickkopf-1（DKK1）蛋白是Wnt /β-catenin信号传导的调节剂，Wnt /β-catenin信号传导参与肿瘤发生和抑制免疫系统。DKK1在肿瘤细胞信号传导和介导免疫抑制性肿瘤微环境中具有重要作用，它可以通过增强髓样来源抑制细胞的活性并下调肿瘤细胞上的NK配体来发挥作用。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1728253, encodeId=cb851e28253f3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 29 11:41:00 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784619, encodeId=a2511e84619d5, content=<a href='/topic/show?id=0845602378' target=_blank style='color:#2F92EE;'>#DKK1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6023, encryptionId=0845602378, topicName=DKK1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Mar 27 01:41:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784620, encodeId=7f911e8462027, content=<a href='/topic/show?id=6d35602e71' target=_blank style='color:#2F92EE;'>#DKN-01#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6027, encryptionId=6d35602e71, topicName=DKN-01)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jan 27 04:41:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738993, encodeId=39301e38993d8, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 10 08:41:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974384, encodeId=811e19e4384b1, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Jun 18 01:41:00 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350834, encodeId=f7f8135083469, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364876, encodeId=f3ae13648e6ea, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454922, encodeId=f9ef145492236, content=<a href='/topic/show?id=f10710e81b3' target=_blank style='color:#2F92EE;'>#LEAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10781, encryptionId=f10710e81b3, topicName=LEAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c32d5614898, createdName=stfoxst, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377823, encodeId=a4fc3e782346, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/05/96674c49cee5700b3883e1c0bf2de935.jpg, createdBy=0c282404630, createdName=170185871_90031502, createdTime=Sun Jan 05 16:43:49 CST 2020, time=2020-01-05, status=1, ipAttribution=)]
    2020-11-29 feather89

    #PE#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1728253, encodeId=cb851e28253f3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 29 11:41:00 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784619, encodeId=a2511e84619d5, content=<a href='/topic/show?id=0845602378' target=_blank style='color:#2F92EE;'>#DKK1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6023, encryptionId=0845602378, topicName=DKK1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Mar 27 01:41:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784620, encodeId=7f911e8462027, content=<a href='/topic/show?id=6d35602e71' target=_blank style='color:#2F92EE;'>#DKN-01#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6027, encryptionId=6d35602e71, topicName=DKN-01)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jan 27 04:41:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738993, encodeId=39301e38993d8, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 10 08:41:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974384, encodeId=811e19e4384b1, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Jun 18 01:41:00 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350834, encodeId=f7f8135083469, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364876, encodeId=f3ae13648e6ea, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454922, encodeId=f9ef145492236, content=<a href='/topic/show?id=f10710e81b3' target=_blank style='color:#2F92EE;'>#LEAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10781, encryptionId=f10710e81b3, topicName=LEAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c32d5614898, createdName=stfoxst, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377823, encodeId=a4fc3e782346, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/05/96674c49cee5700b3883e1c0bf2de935.jpg, createdBy=0c282404630, createdName=170185871_90031502, createdTime=Sun Jan 05 16:43:49 CST 2020, time=2020-01-05, status=1, ipAttribution=)]
    2020-03-27 docwu2019

    #DKK1单抗#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1728253, encodeId=cb851e28253f3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 29 11:41:00 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784619, encodeId=a2511e84619d5, content=<a href='/topic/show?id=0845602378' target=_blank style='color:#2F92EE;'>#DKK1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6023, encryptionId=0845602378, topicName=DKK1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Mar 27 01:41:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784620, encodeId=7f911e8462027, content=<a href='/topic/show?id=6d35602e71' target=_blank style='color:#2F92EE;'>#DKN-01#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6027, encryptionId=6d35602e71, topicName=DKN-01)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jan 27 04:41:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738993, encodeId=39301e38993d8, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 10 08:41:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974384, encodeId=811e19e4384b1, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Jun 18 01:41:00 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350834, encodeId=f7f8135083469, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364876, encodeId=f3ae13648e6ea, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454922, encodeId=f9ef145492236, content=<a href='/topic/show?id=f10710e81b3' target=_blank style='color:#2F92EE;'>#LEAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10781, encryptionId=f10710e81b3, topicName=LEAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c32d5614898, createdName=stfoxst, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377823, encodeId=a4fc3e782346, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/05/96674c49cee5700b3883e1c0bf2de935.jpg, createdBy=0c282404630, createdName=170185871_90031502, createdTime=Sun Jan 05 16:43:49 CST 2020, time=2020-01-05, status=1, ipAttribution=)]
    2020-01-27 qblt

    #DKN-01#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1728253, encodeId=cb851e28253f3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 29 11:41:00 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784619, encodeId=a2511e84619d5, content=<a href='/topic/show?id=0845602378' target=_blank style='color:#2F92EE;'>#DKK1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6023, encryptionId=0845602378, topicName=DKK1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Mar 27 01:41:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784620, encodeId=7f911e8462027, content=<a href='/topic/show?id=6d35602e71' target=_blank style='color:#2F92EE;'>#DKN-01#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6027, encryptionId=6d35602e71, topicName=DKN-01)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jan 27 04:41:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738993, encodeId=39301e38993d8, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 10 08:41:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974384, encodeId=811e19e4384b1, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Jun 18 01:41:00 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350834, encodeId=f7f8135083469, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364876, encodeId=f3ae13648e6ea, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454922, encodeId=f9ef145492236, content=<a href='/topic/show?id=f10710e81b3' target=_blank style='color:#2F92EE;'>#LEAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10781, encryptionId=f10710e81b3, topicName=LEAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c32d5614898, createdName=stfoxst, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377823, encodeId=a4fc3e782346, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/05/96674c49cee5700b3883e1c0bf2de935.jpg, createdBy=0c282404630, createdName=170185871_90031502, createdTime=Sun Jan 05 16:43:49 CST 2020, time=2020-01-05, status=1, ipAttribution=)]
    2020-02-10 124988c7m106暂无昵称

    #ERA#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1728253, encodeId=cb851e28253f3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 29 11:41:00 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784619, encodeId=a2511e84619d5, content=<a href='/topic/show?id=0845602378' target=_blank style='color:#2F92EE;'>#DKK1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6023, encryptionId=0845602378, topicName=DKK1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Mar 27 01:41:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784620, encodeId=7f911e8462027, content=<a href='/topic/show?id=6d35602e71' target=_blank style='color:#2F92EE;'>#DKN-01#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6027, encryptionId=6d35602e71, topicName=DKN-01)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jan 27 04:41:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738993, encodeId=39301e38993d8, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 10 08:41:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974384, encodeId=811e19e4384b1, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Jun 18 01:41:00 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350834, encodeId=f7f8135083469, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364876, encodeId=f3ae13648e6ea, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454922, encodeId=f9ef145492236, content=<a href='/topic/show?id=f10710e81b3' target=_blank style='color:#2F92EE;'>#LEAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10781, encryptionId=f10710e81b3, topicName=LEAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c32d5614898, createdName=stfoxst, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377823, encodeId=a4fc3e782346, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/05/96674c49cee5700b3883e1c0bf2de935.jpg, createdBy=0c282404630, createdName=170185871_90031502, createdTime=Sun Jan 05 16:43:49 CST 2020, time=2020-01-05, status=1, ipAttribution=)]
    2020-06-18 ms24272190615788285182

    #Therapeutic#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1728253, encodeId=cb851e28253f3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 29 11:41:00 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784619, encodeId=a2511e84619d5, content=<a href='/topic/show?id=0845602378' target=_blank style='color:#2F92EE;'>#DKK1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6023, encryptionId=0845602378, topicName=DKK1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Mar 27 01:41:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784620, encodeId=7f911e8462027, content=<a href='/topic/show?id=6d35602e71' target=_blank style='color:#2F92EE;'>#DKN-01#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6027, encryptionId=6d35602e71, topicName=DKN-01)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jan 27 04:41:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738993, encodeId=39301e38993d8, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 10 08:41:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974384, encodeId=811e19e4384b1, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Jun 18 01:41:00 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350834, encodeId=f7f8135083469, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364876, encodeId=f3ae13648e6ea, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454922, encodeId=f9ef145492236, content=<a href='/topic/show?id=f10710e81b3' target=_blank style='color:#2F92EE;'>#LEAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10781, encryptionId=f10710e81b3, topicName=LEAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c32d5614898, createdName=stfoxst, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377823, encodeId=a4fc3e782346, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/05/96674c49cee5700b3883e1c0bf2de935.jpg, createdBy=0c282404630, createdName=170185871_90031502, createdTime=Sun Jan 05 16:43:49 CST 2020, time=2020-01-05, status=1, ipAttribution=)]
    2020-01-07 zhaojie88

    #therapeutics#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1728253, encodeId=cb851e28253f3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 29 11:41:00 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784619, encodeId=a2511e84619d5, content=<a href='/topic/show?id=0845602378' target=_blank style='color:#2F92EE;'>#DKK1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6023, encryptionId=0845602378, topicName=DKK1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Mar 27 01:41:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784620, encodeId=7f911e8462027, content=<a href='/topic/show?id=6d35602e71' target=_blank style='color:#2F92EE;'>#DKN-01#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6027, encryptionId=6d35602e71, topicName=DKN-01)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jan 27 04:41:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738993, encodeId=39301e38993d8, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 10 08:41:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974384, encodeId=811e19e4384b1, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Jun 18 01:41:00 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350834, encodeId=f7f8135083469, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364876, encodeId=f3ae13648e6ea, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454922, encodeId=f9ef145492236, content=<a href='/topic/show?id=f10710e81b3' target=_blank style='color:#2F92EE;'>#LEAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10781, encryptionId=f10710e81b3, topicName=LEAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c32d5614898, createdName=stfoxst, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377823, encodeId=a4fc3e782346, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/05/96674c49cee5700b3883e1c0bf2de935.jpg, createdBy=0c282404630, createdName=170185871_90031502, createdTime=Sun Jan 05 16:43:49 CST 2020, time=2020-01-05, status=1, ipAttribution=)]
    2020-01-07 doctor-chen9582

    #PD-1单抗#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1728253, encodeId=cb851e28253f3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 29 11:41:00 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784619, encodeId=a2511e84619d5, content=<a href='/topic/show?id=0845602378' target=_blank style='color:#2F92EE;'>#DKK1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6023, encryptionId=0845602378, topicName=DKK1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Mar 27 01:41:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784620, encodeId=7f911e8462027, content=<a href='/topic/show?id=6d35602e71' target=_blank style='color:#2F92EE;'>#DKN-01#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6027, encryptionId=6d35602e71, topicName=DKN-01)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jan 27 04:41:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738993, encodeId=39301e38993d8, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 10 08:41:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974384, encodeId=811e19e4384b1, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Jun 18 01:41:00 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350834, encodeId=f7f8135083469, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364876, encodeId=f3ae13648e6ea, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454922, encodeId=f9ef145492236, content=<a href='/topic/show?id=f10710e81b3' target=_blank style='color:#2F92EE;'>#LEAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10781, encryptionId=f10710e81b3, topicName=LEAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c32d5614898, createdName=stfoxst, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377823, encodeId=a4fc3e782346, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/05/96674c49cee5700b3883e1c0bf2de935.jpg, createdBy=0c282404630, createdName=170185871_90031502, createdTime=Sun Jan 05 16:43:49 CST 2020, time=2020-01-05, status=1, ipAttribution=)]
    2020-01-07 stfoxst

    #LEAP#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1728253, encodeId=cb851e28253f3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 29 11:41:00 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784619, encodeId=a2511e84619d5, content=<a href='/topic/show?id=0845602378' target=_blank style='color:#2F92EE;'>#DKK1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6023, encryptionId=0845602378, topicName=DKK1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Mar 27 01:41:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784620, encodeId=7f911e8462027, content=<a href='/topic/show?id=6d35602e71' target=_blank style='color:#2F92EE;'>#DKN-01#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6027, encryptionId=6d35602e71, topicName=DKN-01)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jan 27 04:41:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738993, encodeId=39301e38993d8, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 10 08:41:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974384, encodeId=811e19e4384b1, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Thu Jun 18 01:41:00 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350834, encodeId=f7f8135083469, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364876, encodeId=f3ae13648e6ea, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454922, encodeId=f9ef145492236, content=<a href='/topic/show?id=f10710e81b3' target=_blank style='color:#2F92EE;'>#LEAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10781, encryptionId=f10710e81b3, topicName=LEAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c32d5614898, createdName=stfoxst, createdTime=Tue Jan 07 06:41:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377823, encodeId=a4fc3e782346, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/05/96674c49cee5700b3883e1c0bf2de935.jpg, createdBy=0c282404630, createdName=170185871_90031502, createdTime=Sun Jan 05 16:43:49 CST 2020, time=2020-01-05, status=1, ipAttribution=)]
    2020-01-05 170185871_90031502

    学习了

    0

相关资讯

增强现实公司Magic Leap融资10亿美元，与HoloLens正面PK

2014年10月21日，谷歌曾牵头对Magic Leap进行5.42亿美元投资。尽管人们对Magic Leap给予很高期望，但其长期以来始终保持沉默。直到本周，Magic Leap发布了其首段视频，演示其正在研发的技术。同时，该公司即将完成最新一轮10亿美元融资，这促使该公司估值一跃而达到45亿美元，成为独角兽公司之一。当由Google所支持的增强现实公司Magic Leap悄悄地申请了专

BMC Cancer:拉帕替尼+卡培他滨对某些乳腺癌伴或不伴脑转移患者疗效相同

　　《BMC癌症》（BMC Cancer）杂志近期发表的一项研究表明，拉帕替尼+卡培他滨对某些乳腺癌伴或不伴脑转移（BM）患者的疗效相同。 　　该研究名为拉帕替尼扩展应用计划（the lapatinib expanded access program ，LEAP），是一项全球、单臂、公开标签的研究，纳入了蒽环类+紫杉烷+曲妥珠单抗治疗后